George Underwood looks at the rapid growth of patient centricity over the last few years and considers what pharma’s next steps should be to enhance patient engagement.
Developing life-changing treatments for dementia is a team effort that takes commitment from all involved, from charities and patients to pharma and industry.
Patient and public involvement (PPI) may be increasingly seen as the “right thing to do”, but without systematic evaluation how do we stop good intentions becoming tick-box tokenism?
For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s the company’s director of oncology advocacy and government affairs, to talk
Chris Anselmo, who has a rare form of muscular dystrophy, hopes to educate pharma on the patient journey and help new patients cope with a life-changing diagnosis.